Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 5 results for "fresenius kabi oncology"

Human medicines European public assessment report (EPAR): Do...

This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing ... European Medicines Agency, 1 week ago

1 images for "fresenius kabi oncology"

India TV, 6 months ago

Fresenius Kabi Oncology reports net loss of Rs 63.63 crore in the December 2013 quarter

Sales decline 69.90% to Rs 45.27 crore Net loss of Fresenius Kabi Oncology reported to Rs 63.63 crore in the quarter ended December 2013 as against net profit of Rs 48.36 crore during the previous quarter ended December 2012. Sales declined 69.90% to Rs 45.27 ...
 Business Standard2 months ago

Companies skirt delisting norms: Advisory firms

MUMBAI: Shareholder advisory firms have raised concerns over the recent delisting move by certain companies and the route adopted by them to comply with norms. These firms have asked market regulator Sebi to streamline the delisting process which, ...
 Times of India2 weeks ago ASTRAZENECA : Companies skirt delisting norms: Advisory firms  4 Traders2 weeks ago AstraZeneca set to pop delist pill  Calcutta Telegraph1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - fresenius kabi oncology
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less